Arvest Bank Trust Division Sells 519 Shares of IQVIA Holdings Inc. $IQV

Arvest Bank Trust Division decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 84,001 shares of the medical research company’s stock after selling 519 shares during the period. Arvest Bank Trust Division’s holdings in IQVIA were worth $13,238,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Everpar Advisors LLC lifted its stake in shares of IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares during the last quarter. Private Trust Co. NA raised its holdings in IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the period. Ballentine Partners LLC lifted its position in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock worth $260,000 after acquiring an additional 69 shares during the last quarter. Independent Advisor Alliance boosted its holdings in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the period. Finally, Nemes Rush Group LLC grew its position in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. UBS Group upped their price target on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $241.00.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $223.36 on Friday. The stock has a market capitalization of $38.04 billion, a price-to-earnings ratio of 30.64, a price-to-earnings-growth ratio of 2.47 and a beta of 1.34. The business’s fifty day moving average price is $202.05 and its two-hundred day moving average price is $178.04. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $228.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.